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Protein losing enteropathy (PLE) refers to excessive intestinal protein loss, resulting in hypoalbuminemia. Underlying pathologies
include conditions leading to either reduced intestinal barrier or lymphatic congestion. We describe the case of a patient with
long-lasting diffuse abdominal problems and PLE. Repetitive endoscopies were normal with only minimal lymphangiectasia in
biopsies. Further evaluations revealed an indolent marginal zone lymphoma with minor bone marrow infiltration. Monotherapy
with rituximab decreased bone marrow infiltration of the lymphoma but did not relieve PLE. Additional treatments with steroids,
octreotide, a diet devoid of long-chain fatty-acids, and parenteral nutrition did not prevent further clinical deterioration with
marked weight loss (23 kg), further reduction in albumin concentrations (nadir 8 g/L), and a pronounced drop in performance
status. Finally, immunochemotherapy with rituximab and bendamustine resulted in hematological remission and remarkable
clinical improvement. 18 months after therapy the patient remains free of gastrointestinal complaints and has regained his body
weight with normal albumin levels. We demonstrate a case of PLE secondary to indolent marginal zone lymphoma. No intestinal
pathologies were detected, contrasting a severe and almost lethal clinical course. Immunochemotherapy relieved lymphoma and
PLE, suggesting that a high suspicion of lymphoma is warranted in otherwise unexplained cases of PLE.
1. Introduction
Protein losing enteropathy (PLE) comprises excessive loss of
proteins into the gastrointestinal tract resulting in hypopro-
teinemia. A variety of conditions can result in intestinal
leakage via two mechanisms [1]: (i) reduced intestinal barrier
due to mucosal injury and (ii) lymphatic congestion and/or
stasis resulting in increased lymphatic pressure.
Therefore, work-up of PLE includes testing for malig-
nancy, celiac disease, inflammatory bowel-diseases, chronic
infectious diseases, collagenous colitis, allergic gastroen-
teropathy, eosinophilic gastroenteritis, and amyloidosis [1–
10]. Me´ne´trier’s disease characterized by giant mucosal
folds in the stomach might be a common cause of
PLE.
Lymphatic congestion or stasis can result in leakage
of intestinal lymph into the lumen of intestinal organs.
Diagnostic clues for increased lymphatic pressure include
dilated lymphatic vessels (lymphangiectasia) on histological
specimen. Intestinal lymphangiectasia has been described as
a primary condition or as a complication of other diseases
[11]. Secondary causes for increased lymphatic pressure
include cardiac disease, portal hypertension, damage or
injury of retroperitoneal lymph nodes, for instance, after
surgery, chemotherapy or infectious ormalignant conditions,
or Turner’s syndrome [12].
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Table 1: Blood work at presentation in our unit.
Value Reference values
Hemoglobin (g/L) 163 134–170
White blood count (G/L) 9.2 3–9.6
Neutrophils 5.1 1.4–8
Monocytes 0.55 0.16–0.95
Eosinophils 0.35 0–0.7
Basophiles 0.05 0–0.15
Lymphocytes 3.3 1.5–4
Platelets (G/L) 332 143–400
Albumin (g/L) 18 40–49
Protein (g/L) 38 66–87
IgA (g/L) 0.4 0.7–4
IgG (g/L) 1.9 7–16
IgM (g/L) 0.7 0.4–2.3
Fibrinogen (g/L) 2.7 1.5–4
Transferrin (𝜇mol/L) 13 25–50
Chromogranin A (𝜇g/L) 1100 <85
Gastrin (ng/L) 345 13–115
We report the case of severe paraneoplastic PLE in a
patient with marginal zone lymphoma but without gastroin-
testinal lesions. Immunochemotherapy resulted in remission
of lymphoma and relief of all symptoms.
2. Case Presentation
A 47-year-old patient was referred to our outpatient clinic
for evaluation of abdominal complaints since 15 years. The
patient described postprandial nausea with diffuse abdom-
inal pain and diarrhea hours after the meal. Five years ago
the patient noted ankle edema and hypoalbuminemia was
diagnosed.
The patient was a sportive nonsmoker. Medication
included pantoprazole and vitamin supplements. Besides
appendectomy the personal history was unremarkable. Phys-
ical examination revealed mild peripheral edema but no
further findings.
Blood work was remarkable for hypoalbuminemia 18 g/L
(norm 40–49 g/L) and mild iron deficiency. Liver and kidney
function tests and a peripheral blood count were normal
(Table 1). In 24 h stool measurements alpha-1 antitrypsin
clearance was 432mL/d (norm <24mL/d), confirming pro-
tein losing enteropathy. Repetitive stool tests revealed normal
calprotectin levels and no evidence for bacterial or parasitic
infection. An HIV test was negative.
Chromogranin A and Gastrin were repeatedly ele-
vated, most likely due to pantoprazole treatment and 68Ga
DOTATATE-PET-scan did not reveal a neuroendocrine
tumor.
Repetitive upper and lower bowel endoscopy with biop-
sies were unremarkable without signs of Me´ne´trier’s dis-
ease or lymphoma infiltration. Video capsule endoscopy
and single-balloon enteroscopy revealed two small jejunal
ulcerous lesions with unremarkable histology. Minimal lym-
phangiectasia was found on biopsies of the small and large
intestine (Figure 1). Extensive work-up of all biopsies did not
show pathogens, intraepithelial lymphocytosis, deposition of
a paraprotein, or amyloidosis. Neither in abdominal wall
fat pad biopsies amyloid deposits were found. Common
variable immunodeficiency has been excluded after ade-
quate immunologic response to vaccination with diphthe-
ria/tetanus and pneumococci.
Sprue was ruled out by serological testing, HLA analysis,
and intestinal biopsies.
Echocardiogram was unremarkable.
Serum protein electrophoresis was without parapro-
teinemia. Immunofixation demonstrated the presence of a
weak IgM-kappa band. IgM in the serum was not elevated
(0.7 g/L) and free-kappa light chains were slightly elevated
in the serum and the urine (19.5mg/L, norm 3.3–19.4;
urine: 29.4mg/L, norm <7.1). Bone marrow examination was
diagnostic for low-grade B cell non-Hodgkin lymphomawith
minor infiltration (20%) with predominant expression of
IgG-𝜅. Genetic work-up showed monoclonal IgH rearrange-
ment and mutated MYD88 with a normal karyotype. We
diagnosed marginal zone lymphoma although lymphoplas-
macytic lymphoma formally cannot be excluded [13]. FDG-
PET-scan showed increased metabolic activity along several
large intestinal loops but no additional extranodal or nodal
manifestations were found on FDG-PET- or CT-scan. A
lymphography was normal.
Increasing symptoms prompted steroid treatment. Nei-
ther 6 cycles of dexamethasone (40mg i.v. during 4 out of
28 days) nor oral prednisone (7.5mg daily for 6 months)
or budesonide (9mg per day for 1 year) resulted in lasting
improvement. Due to progressive symptoms with increasing
edema and reduced quality of life accompanied by persistent
minor bone marrow infiltration therapy with rituximab (4
cycles of 375mg/m2 once weekly) was started. Even though
this treatment temporarily improved diarrhea, patient dete-
rioration and progressive weight loss of altogether 23 kg
resulted in emergent inpatient admission (Figure 2).
The patient consumed a diet high in protein but low in
long-chain fatty-acids but tolerated very little food. Feeding
via a gastroduodenal tube resulted in worsening diarrhea
and parenteral nutrition was started. A trial of octreotide
(0.1mg three times per day s.c. over 10 days) did not
relieve symptoms. Progressive deterioration and hypotension
prompted temporary treatment at an intensive-care unit.
A repeat bone marrow examination revealed minimal
infiltration by the lymphoma, only detectable by flow cytom-
etry. After exclusion of all alternative explanations for PLE,
immunochemotherapy (rituximab 375mg/m2 every 4 weeks,
bendamustine 90mg/m2 days 1 and 2 for a total of six
months) was started. After one cycle, bone marrow exam-
ination showed complete response with improvement in
performance, body weight, and edema.
20 months after completion of immunochemotherapy,
lymphoma shows ongoing morphological, immunopheno-
typical, and molecular (MYD88 PCR) remission. The patient
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Figure 1: Small bowel (a) and large bowel (b) biopsy samples with minimal ectasia of lymphatic vessels (arrowheads) without other
histopathologic findings (H&E). Bone marrow biopsy (c and d) with monotonous infiltrates of a low-grade non-Hodgkin lymphoma (c;
H&E), highlighted by immunohistochemistry (d; B cell marker CD79a) (arrowheads). Scale bars = 100𝜇m.
regained full performance status and body weight with nor-
mal serum albumin levels (Figure 2). The patient still notes
occasional diarrhea which does not disturb daily activities.
He provided written informed consent for publication of this
case.
3. Discussion
We present the case of a patient with PLE secondary to
marginal zone lymphoma. Protein losing enteropathy and
intestinalmalfunction resulted in pronounced clinical deteri-
oration. Careful exclusion of virtually all alternative diagnosis
and relief of PLE symptoms after treatment of lymphoma
provide strong evidence of a causal relationship between
marginal zone lymphoma and PLE in this patient.
Protein losing enteropathy was suspected due to the
combination of low albumin and reduced serum levels of IgA,
IgG, IgM, and transferrin combined with gastrointestinal
symptoms. Proof of PLE was provided by determination
of alpha-1 antitrypsin clearance which is excreted in the
stool but not degraded [14, 15]. Normal values for alpha-
1 antitrypsin clearance are 24mL/day in patients without
diarrhea and 56mL/day in patients with diarrhea [16] and
measurements in our patient were clearly above this level.
How B cell lymphoma caused PLE in our patient remains
unclear but several potential mechanisms exist: (i) affection
of intestinal lymph nodes resulting in lymphatic stasis, (ii)
lymphatic hyperviscosity syndrome due to IgM paraprotein,
(iii) epithelial deposition of the paraprotein, (iv) direct infil-
tration of themucosa by lymphoma cells, (v) aberrant activity
of the paraprotein, and (vi) paraneoplastic effect mediated by
cytokines or by immune response to lymphoma.
In our patient an extensive work-up excluded several of
the mechanisms described above. Imaging of lymph nodes
was normal and none of the biopsies revealed pronounced
lymphangiectasia. Concentrations of the paraprotein were
consistently extremely low and no hyperviscosity syndrome
was present. Epithelial deposition and mucosal infiltration
were excluded by endoscopy with multiple biopsies and
immunohistochemistry was negative for IgM deposition.
Congo red staining was negative for amyloidosis in the
intestinal mucosa and in abdominal fat. There was little
association between extent of bonemarrow infiltration by the
lymphoma and severity of the patient’s symptoms.
PLE has been described as a rare complication of B cell
neoplasms. The largest case series summarizes 25 current
and historical cases with Waldenstrom’s macroglobulinemia
and variable concentrations of IgM paraprotein [17]. In
most patients intestinal lymphangiectasia was apparent on
intestinal biopsies and immunohistochemistry demonstrated
IgM deposition in intestinal lymphatic vessels. The authors
speculate that mucosal IgM production would lead to accu-
mulation of the IgM paraprotein in the intestinal lymphatic
system and subsequent stasis.
Case reports demonstrated PLE in the setting of a grade
II follicular non-Hodgkin lymphoma with pronounced duo-
denal B cell follicles and retroperitoneal lymph nodes [18] as
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Figure 2: Evolution of representative disease markers. Courses
of Karnofsky index, body weight, serum albumin, bone marrow
infiltration, and timing of treatment are indicated. Please note
different units of all markers (% for Karnofsky index and bone
marrow infiltration, kg for bodyweight, and g/L for serumalbumin).
RTX: rituximab; benda: bendamustine.
well as a stage IVa non-Hodgkin lymphoma with retroperi-
toneal lymphadenopathy [19], respectively, with response to a
treatment with rituximab CHOP. In another case of follicular
lymphoma direct leakage of lymph from the duodenal bulb
was observed [20].
Primary intestinal lymphangiectasia (PIL) is a rare con-
dition [11] that can be complicated by the development of
lymphoma [21, 22]. It remains unclear whether in these
cases lymphangiectasia promotes lymphoma or an indolent
lymphoma precedes lymphangiectasia. Reports of successful
resolution of PIL-symptoms after lymphoma treatment [21]
raise the possibility that some cases of PIL actually represent
lymphoma associated PLE.
Treatment of PLE should focus on the underlying condi-
tion. Supportive treatment includes a low-fat, high-protein,
medium triglyceride supplement diet [23] which has been
ineffective in our patient. Octreotide has been used success-
fully in patients with primary intestinal lymphangiectasia
[24], Me´ne´trier’s disease [25], or amyloidosis [26] but did not
affect symptoms in our patient. In our case even gastric or
jejunal feeding and parenteral nutrition could not stop pro-
gressive deterioration. Finally, immunochemotherapy was
started which resulted in a lasting remission of all symptoms.
Our case is remarkable for several reasons. (i) PLE was
severe and almost lethal in our patient with an otherwise
indolent lymphoma. (ii) Despite extensive investigations no
macroscopic affection of the intestine was evident and intesti-
nal lymphangiectasia was mild at best. Therefore, our case
confirms that lymphoma can cause PLEwithoutmacroscopic
lesions, without pronounced lymphangiectasia, and without
enlarged intestinal lymph nodes. To the best of our knowl-
edge, in all cases with lymphoma and PLE at least one of these
pathologies had been present. (iii) The bone marrow was the
only site where lymphoma was detectable. The lymphoma
mass was low, suggesting that PLE was caused by humoral
factors secreted by lymphoma cells (e.g., interleukins) or an
immune response. (iv) To the best of our knowledge no PLE
secondary to marginal zone lymphoma has been described
previously.
Our case report has several limitations. (i) No surgical
specimen and no biopsies of intestinal lymph nodes are
available and infiltration of deeper lymphatic vessels by B cells
remain possible. (ii) Pathological assessment of intestinal
lymphangiectasia has not been standardized and our patho-
logical assessment might differ from assessments in other
case reports or case series. (iii) Limited conclusions can be
drawn from a single case.
In summary, we report the case of a patient with severe
protein losing enteropathy due to marginal zone lymphoma
which was successfully treated with immunochemotherapy.
Hidden B cell lymphoma should be considered if no cause
of PLE is apparent after work-up of a patient. Due to lack of
detectable intestinal lesions during endoscopic investigations
and with most imaging techniques a high level of suspicion
for lymphoma is warranted in all cases of unexplained PLE
after standard evaluations.
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